Passa al contenuto
Merck

A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.

Cancer discovery (2015-02-19)
Shane Stegeman, Ernest Amankwah, Kerenaftali Klein, Tracy A O'Mara, Donghwa Kim, Hui-Yi Lin, Jennifer Permuth-Wey, Thomas A Sellers, Srilakshmi Srinivasan, Rosalind Eeles, Doug Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G Giles, Fredrik Wiklund, Henrik Gronberg, Christopher A Haiman, Johanna Schleutker, Børge G Nordestgaard, Ruth C Travis, David Neal, Paul Pharoah, Kay-Tee Khaw, Janet L Stanford, William J Blot, Stephen Thibodeau, Christiane Maier, Adam S Kibel, Cezary Cybulski, Lisa Cannon-Albright, Hermann Brenner, Radka Kaneva, Manuel R Teixeira, Amanda B Spurdle, Judith A Clements, Jong Y Park, Jyotsna Batra
ABSTRACT

Prostate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identified 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3' untranslated region of genes predicted to affect miRNA binding (miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated (P<2.3×10(-5)) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specific affinity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affinity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role. Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Sodio dodecil solfato, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ACS reagent, ≥99.0%
Supelco
Sodio dodecil solfato, dust-free pellets, suitable for electrophoresis, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ≥98.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Sodio dodecil solfato, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
Sodio dodecil solfato, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
Sodio dodecil solfato, BioXtra, ≥99.0% (GC)
Supelco
Sodio dodecil solfato, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
Sodio dodecil solfato, ≥90% ((Assay))
Sigma-Aldrich
Sodio dodecil solfato, ≥98.0% (GC)
Sodio dodecil solfato, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodio dodecil solfato, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC), free-flowing, Redi-Dri